Brain chemistry, drugs and disease
Studying this course? Keep your progress in one place.
Key facts
- Each brain pathway relies on a balance of neurotransmitters; too little or too much disrupts transmission.
- Parkinson's disease: dopamine-releasing neurones die, so less dopamine is released.
- L-Dopa is a precursor that crosses the blood-brain barrier and is converted into dopamine.
- SSRIs block serotonin reuptake, so serotonin stays in the cleft longer.
- MDMA blocks reuptake and causes serotonin release, then depletes it.
- New drugs go through laboratory, animal and double-blind clinical trials.
Neurotransmitters and ill health
If too little or too much transmitter is released, removed or detected, transmission is disrupted and disease can result.
Each pathway needs a balance of neurotransmitters.
- Dopamine controls movement and reward. Too little contributes to Parkinson's disease.
- Serotonin affects mood, sleep and appetite. Low levels in some synapses are linked with depression.
Dopamine
- Controls movement and reward
- Too little: Parkinson's disease
Serotonin
- Affects mood, sleep, appetite
- Low levels: depression
Which neurotransmitter is too low in Parkinson's disease?
Dopamine and Parkinson's
Dopamine-releasing neurones in the substantia nigra die, so motor pathways are stimulated less.
In Parkinson's disease, neurones in the substantia nigra (part of the basal ganglia) die and less dopamine reaches the motor pathways.
Symptoms are tremor, rigidity and slow movement. It is progressive, as more neurones die over time.
- 1
Neurones die
dopamine-releasing neurones in substantia nigra
- 2
Less dopamine
released into motor pathway synapses
- 3
Less stimulation
postsynaptic neurones stimulated less
- 4
Symptoms
tremor, rigidity, slow movement; progressive
Where do the neurones die in this disease?
L-Dopa
L-Dopa crosses the blood-brain barrier and is converted into dopamine, treating symptoms but not the disease.
Dopamine itself cannot cross the blood-brain barrier. L-Dopa is a precursor that crosses it and is converted into dopamine in the brain.
Symptoms improve, but as more neurones die, higher doses are needed. High doses cause side effects such as involuntary movements and nausea.
- 1
Taken as L-Dopa
dopamine cannot cross the barrier
- 2
Crosses barrier
enters the brain
- 3
Converted
made into dopamine
- 4
Symptoms improve
higher doses needed over time
Why does L-Dopa need higher doses over time?
Serotonin and SSRIs
SSRIs block reuptake transporter proteins, so serotonin stays in the cleft longer and stimulates postsynaptic receptors more.
Some people with depression have a lower serotonin concentration in certain synapses. SSRIs (e.g. fluoxetine) bind to reuptake transporter proteins in the presynaptic membrane.
Effects take weeks and not all patients respond, so serotonin is one factor, and the link is a correlation.
- 1
SSRI binds
reuptake transporter proteins
- 2
Reuptake blocked
serotonin not taken back
- 3
Stays in cleft
higher concentration for longer
- 4
More stimulation
postsynaptic receptors
Why do SSRIs raise serotonin in the cleft?
MDMA
MDMA mimics serotonin, blocks reuptake and causes extra release, then leaves stores depleted.
MDMA has a similar shape to serotonin and binds to the transporter proteins, blocking reuptake and causing extra serotonin to be released. Postsynaptic neurones are overstimulated, causing euphoria.
Afterwards stores are depleted, so users may feel low in mood for days. It also raises body temperature.
- 1
Binds
similar shape to serotonin
- 2
Extra release
reuptake blocked
- 3
Overstimulation
euphoria and energy
- 4
After effects
stores depleted, low mood
Why may a user feel low in mood after MDMA wears off?
Developing new drugs
Drugs can block or mimic a transmitter, block reuptake or breakdown, or supply a precursor, then are tested in stages.
Knowing how synapses work lets researchers design drugs, for example by blocking reuptake or breakdown or supplying a precursor.
Testing goes from laboratory studies to animals to clinical trials, often double-blind with a placebo. Drugs often have side effects.
- 1
Laboratory
studies
- 2
Animals
tests
- 3
Clinical trial
humans, often double-blind with a placebo
- 4
Approval
safety and effectiveness checked
Why is a placebo used in a clinical trial?
Try an exam question
Explain how L-Dopa can reduce the symptoms of Parkinson's disease.
[4 marks]
- [1]Parkinson's disease is caused by death of dopamine-releasing neurones, so less dopamine is released.
- [1]Dopamine cannot cross the blood-brain barrier but L-Dopa can.
- [1]L-Dopa is converted into dopamine in the brain.
- [1]More dopamine is released into synapses, restoring stimulation of postsynaptic neurones.
That's the notes covered.
Carry on to the next subtopic.
Try a question
Which statement best explains the symptoms of the patient?
1 mark, marked against the mark scheme
Which statement best explains the symptoms of the patient?
1 mark, marked against the mark scheme